Inhibikase Therapeutics IKT
NASDAQ IKT
$2.00 +0.07 (+3.63%)
At close: Oct 2, 2026 · 4:00 PM EDT

Inhibikase Therapeutics (IKT) Return on Assets [ROA] (2021 - 2026)

Updated

Inhibikase Therapeutics (IKT) recorded Return on Assets [ROA] of -38.84% in Q2 2026, up 9.41 percentage points from -48.26% a year earlier but down 7.69 percentage points from the prior quarter.

Analysis

Inhibikase Therapeutics (IKT) Return on Assets [ROA] (2021 - 2026) Analysis & Trends

For FY2025, Inhibikase Therapeutics reported Return on Assets [ROA] of -37.15%, up 13.40 percentage points from FY2024.

  • Annual Return on Assets [ROA] has a four-year change of +14.50 percentage points (FY2021 to FY2025).
  • Across earlier years, Return on Assets [ROA] came in at -50.55% in FY2024 (+51.32 pp), -101.87% in FY2023 (-48.08 pp), -53.79% in FY2022 (-2.14 pp) and -51.65% in FY2021.
  • Quarterly Return on Assets [ROA] has ranged from -303.91% in Q3 2024 to -23.04% in Q3 2021 over the past five years.
  • On a year-over-year basis, Return on Assets [ROA] has increased for seven consecutive quarters, with an average year-over-year change of +50.22 percentage points over the last eight quarters.
  • Peak year-over-year performance for Return on Assets [ROA] in the last five years was a gain of 243.21 percentage points in Q3 2025, against a drop of 204.38 percentage points in Q3 2024 at the low end.
  • Per Business Quant, the preceding three quarters came in at -31.15% (Q1 2026), -39.86% (Q4 2025) and -60.70% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROA (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn 20.64%
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn 10.47%
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn 4.65%
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn 2.45%
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn 28.37%
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn 9.10%
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn 9.29%
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn -6.13%
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn 2.14%
10 Inhibikase Therapeutics 336.92 Mn -248.55 Mn - -38.84%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -38.84%
Mar 31, 2026 -31.15%
Dec 31, 2025 -39.86%
Sep 30, 2025 -60.70%
Jun 30, 2025 -48.26%
Mar 31, 2025 -39.82%
Dec 31, 2024 -55.53%
Sep 30, 2024 -303.91%
Jun 30, 2024 -191.06%
Mar 31, 2024 -157.63%
Dec 31, 2023 -124.06%
Sep 30, 2023 -99.54%
Jun 30, 2023 -78.19%
Mar 31, 2023 -68.49%
Dec 31, 2022 -67.68%
Sep 30, 2022 -60.14%
Jun 30, 2022 -51.93%
Mar 31, 2022 -41.53%
Dec 31, 2021 -33.48%
Sep 30, 2021 -23.04%
API Access

Inhibikase Therapeutics Return on Assets [ROA] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-assets-%5Broa%5D&ticker=IKT&period=max&api_key=YOUR_API_KEY